Brief: Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations

Ligand Pharmaceuticals Incorporated

01/12/2023 14:20

Dec 1 (Reuters) - Ligand Pharmaceuticals Inc  LGND.O :
    * PALVELLA THERAPEUTICS AND LIGAND PHARMACEUTICALS EXPAND
STRATEGIC PARTNERSHIP TO ACCELERATE PHASE 3 DEVELOPMENT OF
QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS AND
ADDITIONAL HIGH UNMET NEED CLINICAL INDICATIONS
    * LIGAND PHARMACEUTICALS INC - PALVELLA RECEIVED $5 MILLION
UPFRONT PAYMENT
    * LIGAND PHARMACEUTICALS INC - LIGAND'S EXISTING TIERED
ROYALTY ON
WORLDWIDE COMMERCIAL SALES OF QTORIN RAPAMYCIN INCREASED TO
8.0-9.8%
    * LIGAND PHARMACEUTICALS- GRANTED OPTION TO BUY SINGLE-DIGIT
ROYALTY ON EACH NOVEL TOPICAL PRODUCT CANDIDATE GENERATED FROM
PALVELLA'S QTORIN™ PLATFORM

Source text for Eikon:  ID:nGNX8vfZS1 
Further company coverage:  LGND.O 

 ((Reuters.Briefs@thomsonreuters.com;))